https://www.selleckchem.com/peptide/avexitide.html
The coronavirus disease 2019 (COVID-19) pandemic continues to afflict millions of people worldwide. Patients with end-stage heart failure and left ventricular assist devices (LVADs) may be at risk for severe COVID-19 given a high prevalence of complex comorbidities and functional impaired immunity. The objective of this study is to describe the clinical characteristics and outcomes of COVID-19 in patients with end-stage heart failure and durable LVADs. The Trans-CoV-VAD registry is a multi-center registry of LVAD and cardiac transplant
Like
Comment
Share
